Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Cormark reduced their Q1 2017 EPS estimates for Cipher Pharmaceuticals in a note issued to investors on Monday. Cormark analyst D. Novak now anticipates that the brokerage will post earnings of $0.05 per share for the quarter, down from their previous estimate of $0.08. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.03 EPS, Q3 2017 earnings at $0.06 EPS, Q4 2017 earnings at $0.03 EPS and FY2017 earnings at $0.17 EPS.
A number of other equities analysts have also recently issued reports on the company. TD Securities restated a “buy” rating and set a $7.50 target price on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. GMP Securities restated a “hold” rating on shares of Cipher Pharmaceuticals in a report on Saturday, August 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Cipher Pharmaceuticals currently has an average rating of “Hold” and an average target price of $6.85.
Cipher Pharmaceuticals (NASDAQ:CPHR) traded up 2.079% during trading on Tuesday, reaching $3.879. The company had a trading volume of 1,871 shares. The company has a 50 day moving average price of $4.05 and a 200 day moving average price of $5.09. Cipher Pharmaceuticals has a 52-week low of $3.55 and a 52-week high of $6.37. The company’s market capitalization is $101.61 million.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.